Abstract
We read with interest the recent paper of Yamato et al. [1] describing differences in the N-desethyl-amiodarone (DEA) to amiodarone (AMD) ratio in patients with thyroid dysfunction, based on laboratory data, vs. euthyroid patients during AMD treatment.
Original language | English |
---|---|
Pages (from-to) | 1051-1052 |
Number of pages | 2 |
Journal | European Journal of Clinical Pharmacology |
Volume | 73 |
Issue number | 8 |
DOIs | |
Publication status | Published - 1 Aug 2017 |
Keywords
- Amiodarone
- Thyroid Dysfunction
- N-desethyl-amiodarone
- drug-induced toxicity
- regulating exposure